SEC Form 4 · accession 0001140361-18-033093

ANGIODYNAMICS INC · ANGO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and CEO · Director

Period of report

Jul 18, 2018

Accepted (ET)

Jul 20, 2018 · 9:36 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001275187

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jul 18, 2018	A	17,469	$0.00	A	129,286	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option (right to buy)^F2	$20.93	Jul 18, 2018	A	55,651	A	Jul 18, 2019	Jul 18, 2028	Common Stock	55,651	55,651	D
Performance Right^F3	—	Jul 18, 2018	A	34,938	A	—	—	Common Stock	34,938	34,938	D

F1This acquisition of 17,469 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 17,469 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 18, 2019, such that 25% of the restricted stock units will vest on each of July 18, 2019, 2020, 2021 and 2022.
F2These stock options vest in four equal annual installments beginning on July 18, 2019, such that 25% of the options will vest on each of July 18, 2019, 2020, 2021 and 2022.
F3Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.